MarketPulse

pharmaceutical pipeline

6 articles
The Motley FoolThe Motley Fool··Adria Cimino

Pfizer at a Crossroads: Patent Cliffs and Pipeline Bets Define Next Chapter

Pfizer faces patent cliffs and COVID vaccine decline, betting on oncology and obesity drug pipelines to drive future growth amid acquisition integration challenges.
PFELLYNVOclinical trialsacquisitions
BenzingaBenzinga··Vandana Singh

Eli Lilly Poised to Challenge AstraZeneca in Abivax Bidding War

AstraZeneca has exclusive access to Abivax data until March 23. If it misses deadline, Eli Lilly could rejoin bidding for French biotech valued by 1,600% surge.
LLYAZNABVXacquisitionbiotech
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Pfizer and Novo Nordisk: Undervalued Pharma Giants Poised for Rebounds

Pfizer and Novo Nordisk trade at 9x-10.5x forward earnings with deep pipelines offering long-term value potential despite recent underperformance.
PFELLYNVOclinical trialshealthcare stocks
BenzingaBenzinga··Prnewswire

Orexo Restructures Leadership to Pivot Toward Drug Development After Zubsolv Sale

Orexo restructures leadership and divests Zubsolv to focus on drug development and AmorphOX technology advancement.
ORXOYproduct developmentorganizational restructuring
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Acute Ischemic Stroke Market Set for Double-Digit Growth as Novel Therapies Advance

Acute ischemic stroke market poised for significant growth through 2036, driven by novel therapies including recently approved tenecteplase and promising pipeline candidates addressing 1.8 million annual cases.
BMYCELGrAZNDMACclinical trialsmarket growth
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly Strengthens Market Position With Weight-Loss Drug Success

Eli Lilly strengthens market position with blockbuster weight-loss drug Zepbound, diversified pipeline, and AI integration, supporting consistent financial performance and shareholder returns.
LLYdividend growthweight loss drugs